CGM is a Tool, Not a Reward. Unjustified Insurance Coverage Criteria Limit Access to CGM
Recommended Citation
Kruger D, and Anderson JE. CGM is a Tool, Not a Reward. Unjustified Insurance Coverage Criteria Limit Access to CGM. Diabetes Technol Ther 2021.
Document Type
Article
Publication Date
6-23-2021
Publication Title
Diabetes technology & therapeutics
Abstract
Recent studies have demonstrated the clinical utility of continuous glucose monitoring (CGM) use in type 2 diabetes (T2D) who are treated with intensive insulin management. Large retrospective database analyses of T2D patients treated with less-intensive therapies have also shown that CGM use was associated with significant reductions in HbA1c levels and health resource utilization, including diabetes-related hospitalizations/emergency room care. Despite the growing body of evidence supporting CGM use in the broader T2D population, current eligibility criteria required by public and many private insurers are denying millions of individuals with T2D access to this valuable technology. In this article, we discuss an evidence-based rationale for modifying current eligibility requirements for CGM coverage.
PubMed ID
34160300
ePublication
ePub ahead of print
